Clinical Trial Update: Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study evaluating the BTK inhibitor PCI-32765 (ibrutinib) in combination with FCR or BR regimens in chronic lymphocytic leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• PCI-32765 (ibrutinib) (ibrutinib)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2014-07-24